BriaCell Therapeutics (BCTX) Prices $4.7 Million Share Offering; Stock Falls

BriaCell Therapeutics Corp. (NASDAQ: BCTX) priced a public offering of its common shares on June 1, 2026, expecting gross proceeds of approximately $4.7 million, sending its stock lower in early trading. The immunotherapy company said the offering consists of shares sold at a fixed price, with additional details, including the number of shares, to be disclosed in a regulatory filing. The transaction is expected to close on or about June 3, 2026. BriaCell plans to use the net proceeds for working capital and general corporate purposes. BCTX shares fell sharply in premarket action, reflecting typical dilution concerns. The stock had been under pressure prior to the announcement amid a broader biotech sell-off.